Daily Aspirin intake slashes colon cancer relapse risk by 55%
9 hours ago
- #precision-medicine
- #colorectal-cancer
- #aspirin
- A low dose of aspirin halves the risk of recurrence after surgery in colorectal cancer patients with specific genetic mutations in the PIK3 signaling pathway.
- The ALASCCA trial, a randomized clinical study, confirmed the benefits of aspirin, reducing recurrence risk by 55% in patients with the PIK3 mutation.
- Aspirin's potential mechanisms include reducing inflammation, inhibiting platelet function, and tumor growth, making the environment less favorable for cancer.
- The study involved over 3,500 patients from 33 hospitals across Sweden, Norway, Denmark, and Finland.
- Aspirin is globally available and inexpensive compared to modern cancer drugs, making it a promising treatment option.
- Common side effects of aspirin include stomach problems and increased bleeding tendency, and it should be avoided by people with certain conditions like stomach ulcers or bleeding disorders.